AB Science
OTCMKTS:ABSCFAB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
Canaan
NASDAQ:CANCanaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has operations in the United States, Australia, Kazakhstan, Hong Kong, Canada, Mainland China, Thailand, Sweden, and internationally. Canaan Inc. was founded in 2013 and is based in Singapore.
Colossus Minerals
TSE:CSIColossus Minerals Inc. (Colossus) is a development-stage mining company. Colossus is focused on its Serra Pelada project into production. The Serra Pelada Project is located in the mineral prolific Carajas region in Para, Brazil, is host to high grade gold and platinum group metals deposit. The Company's three mineral properties in Brazil: the Serra Pelada Project, the Rio Cristalino Property and the Cutia Property. The Serra Pelada Project is the only material property of the Company. The Company's subsidiaries include Colossus Mineracao Ltda., Mineracao Fazenda Monte Belo Ltda., Serra Pelada - Companhia de Desenvolvimento Mineral, and Grifo Geologia e Participacoes Ltda. In January 2012, the Company acquired Cutia Property from Cooperativa Mista do Garimpeiro de Cutia.
4Front Ventures
OTCMKTS:FFNTF4Front Ventures Corp. owns and manages licensed cannabis facilities in state-licensed markets in the United States. The company operates in two segments, THC Cannabis and CBD Wellness. THC Cannabis segment engages in the cultivation, production, manufacturing, and distribution of THC cannabis products to owned dispensaries and third party retailers; and provision of ancillary services. This segment also sells equipment, supplies, and intellectual property to cannabis producers; and leases real estate properties. In addition, it operates dispensaries in the Massachusetts, Illinois, and Michigan primarily under the MISSION brand name. The CBD Wellness segment sells non-THC hemp derived products. 4Front Ventures Corp. was founded in 2011 and is based in Phoenix, Arizona.
1933 Industries
OTCMKTS:TGIFF1933 Industries Inc., together with its subsidiaries, engages in the cultivation and production of cannabis products in the United States. It operates in three segments: the Medical Segment, the Recreational Segment, and the CBD-Infused Products Segment. The company produces, packages, and markets cannabidiol (CBD)-infused products, including tinctures, vape pens and cartridges, lotions, pain creams, gummies, and capsules under the Canna Hemp and Canna Hemp X brand names. It also offers craft-style cannabis, infused pre-rolls, full spectrum oils, distillates, terpenes, and vaporizer products; and boutique concentrates, such as shatters, crumbles, batters, sugar waxes, diamonds, and cured and live resins under the AMA and Level X brand names. The company offers its products through retail dispensaries and retail outlets, as well as through its e-commerce platform. The company was formerly known as Friday Night Inc. and changed its name to 1933 Industries Inc. in September 2018. 1933 Industries Inc. is headquartered in Vancouver, Canada.